• 1
    Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumour resistance and novel strategies for modulating its activity. Ann Oncol 2002;13:84151.
  • 2
    Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochim Biophys Acta 1998;1400:10719.
  • 3
    O’Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998; 34:15008.
  • 4
    Wilkinson K. Irinotecan hydrochloride. Clin J Oncol Nurs 2001;5:17981.
  • 5
    Hecht JR. Gastrointestinal toxicity of irinotecan. Oncology 1998;12:728.
  • 6
    McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene? J Clin Oncol 2004;22:13569.
  • 7
    Toffoli G, Cecchin E, Corona G, Boiocchi M. Pharmacogenetics of irinotecan. Curr Med Chem Anticancer Agents 2003;3:22537.
  • 8
    Aiuti F, Cerottini JC, Coombs RRA et al. Identification, enumeration and isolation of B and T lymphocytes from human peripheral blood. Report of a WHO/IARC-Sponsored Workshop on Human B and T Cells, London, 15–17 July 1974. Scand J Immunol 1974;3:52132.
  • 9
    Duke RC, Cohen JJ. Morphological and biochemical assays of apoptosis. In: ColiganJE, KruisbealAM (eds) Current Protocols in Immunology. John Willey and Sons, New York, 1992;13.
  • 10
    Singh NP, McCoy MT, Tice RR, Schneider LL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:18491.
  • 11
    Wojewódzka M, Gradzka I, Buraczewska I. Modified neutral comet assay for human lymphocytes. Nukleonika 2002;47:15.
  • 12
    Albertini RJ, Anderson D, Douglas GR et al. ICPS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat Res 2000;463:11172.
  • 13
    International Atomic Energy Agency (IAEA). Cytogenetic Analysis for Radiation Dose Assessment: A Manual, Technical Reports Series No. 405. IAEA, Vienna, Austria, 2001.
  • 14
    Tucker JD, Morgan WF, Awa AA et al. A proposed system for scoring structural aberrations detected by chromosome painting. Cytogenet Cell Genet 1995;68:21121.
  • 15
    Latt S, Allen J, Bloom SE et al. Sister chromatid exchanges: a report of the gene-tox program. Mutat Res 1981;87:1762.
  • 16
    Perry P, Wolff S. New Giemsa method for the differential staining of sister chromatids. Nature 1974;261:1568.
  • 17
    Lamberti L, Bigatti Ponzetto P, Ardito G. Cell kinetics and sister-chromatid exchange frequency in human lymphocytes. Mutat Res 1983;120:1939.
  • 18
    Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res 1985;147:2936.
  • 19
    Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S, Zeiger E. HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 2003;534:6575.
  • 20
    Eastmond DA, Tucker JD. Identification of aneuploidy-inducing agents using cytokinesis-blocked human lymphocytes and antikinetochore antibody. Environ Mol Mutagen 1989;13:3443.
  • 21
    Ellman GL, Courtney KD, Andres VJ, Featherstone RM. A new and rapid colorimetric detremination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:8895.
  • 22
    Morton CL, Wadkins RM, Danks MK, Potter PM. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalysed to SN-38 by butyrylcholinesterase. Cancer Res 1999;59:145863.
  • 23
    Dodds HM, Rivory LP. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol 1999;56:134653.
  • 24
    Godard T, Deslandes E, Sichel F, Poul JM, Gauduchon P. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat Res 2002;520:4756.
  • 25
    Liu LF, Desai SD, Li TK, MaoY, Sun M, Sim SP. Mechanism of action of camptothecin. Ann N Y Acad Sci 2000;922:110.
  • 26
    Pizzolato JF, Saltz L. The camptothecins. Lancet 2003;361:223542.
  • 27
    Pfeiffer P, Goedecke W, Obe G. Mechanisms of DNA double strand break repair and their potential to induce chromosomal aberrations. Mutagenesis 2001;15:289302.
  • 28
    Tice RR. The single cell gel/comet assay: a microgel electrophoretic technique for the detection of DNA damage and repair in individual cells. In: PhillipsDH, VennitS (eds) Environmental Mutagenesis. Bios Scientific Publishers Ltd., Oxford, UK, 1995;31539.
  • 29
    Sané AT, Cantin AM, Paquette B, Wagner JR. Ascorbate modulation of H2O2 and camptothecin-induced cell death in Jurkat cells. Cancer Chemother Pharmacol 2004;54:31521.
  • 30
    Yoshida A, Ueda T, Wano Y, Nakamura T. DNA damage and cell killing by camptothecin and its derivative in human leukaemia HL-60 cells. Jpn J Cancer Res 1993;84:56673.
  • 31
    Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1998;1400:195211.
  • 32
    Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase I: evidence for cell cycle independent toxicity. J Cell Biol 1996;134:75770.
  • 33
    Mosesso P, Fonti E, Bassi L, Lorenti Garcia C, Palitti F. The involvement of chromatin condensation in camptothecin-induced chromosome breaks in G0 human lymphocytes. Mutagenesis 1999;14:1035.
  • 34
    Morton NE. Parameters of the human genome. PNAS 1991;88:747476.
  • 35
    Hoffmann GR, Sayer AM, Joiner EE, McFee AF, Littlefield LG. Analysis by FISH of the spectrum of chromosome aberrations induced by X-rays in G0 human lymphocytes and their fate through mitotic divisions in culture. Environ Mol Mutagen 1999; 33:94110.
  • 36
    Boei JJ, Vermeulen S, Fomina J, Natarajan AT. Detection of incomplete exchanges and interstitial fragments in X-irradiated human lymphocytes using a telomeric PNA probe. Int J Radiat Biol 1998;73:599603.
  • 37
    Deng W, Lucas JN. Combined FISH with pan-telomeric PNA and whole chromosome-specific DNA probes to detect complete and incomplete chromosomal exchanges in human lymphocytes. Int J Radiat Biol 1999;75:110712.
  • 38
    Ganguly BB, Romm H, Pressl S, Stephan G. Involvement of specific chromosomes in radiation-induced rearrangements detected by fluorescence in situ hybridization (FISH). J Environ Pathol Toxicol Oncol 2000;19:31923.
  • 39
    Braselmann H, Kulka U, Huber R, Figel HM, Zitzelsberger H. Distribution of radiation-induced exchange aberrations in all human chromosomes. Int J Radiat Biol 2003;79:393403.
  • 40
    Anderson RM, Sumption ND, Papworth DG, Goodhead DT. Chromosome breakpoint distribution of damage induced in peripheral blood lymphocytes by densely ionizing radiation. Int J Radiat Biol 2006;82:4958.
  • 41
    Boei JJ, Vermeulen S, Natarajan AT. Differential involvement of chromosomes 1 and 4 in the formation of chromosomal aberrations in human lymphocytes after X-irradiation. Int J Radiat Biol 1997;72:13945.
  • 42
    Puerto S, Surralles J, Ramirez MJ, Carbonell E, Creus A, Marcos R. Analysis of bleomycin- and cytosine arabinoside-induced chromosome aberrations involving chromosomes 1 and 4 by painting FISH. Mutat Res 1999;439:311.
  • 43
    Satoh T, Hatanaka M, Yamamoto K, Kuro M, Sofuni T. Application of mFISH for the analysis of chemically induced chromosomal aberrations: a model for the formation of triradial chromosomes. Mutat Res 2002;504:5765.
  • 44
    Kojima A, Shinkai T, Saijo N. Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes. Jpn J Clin Oncol 1993;23:11622.
  • 45
    Karaberis E, Mourelatos D. Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics. Teratogen Carcinogen Mutagen 2000;20:1416.
  • 46
    Bruno S, Giaretti W, Darzynkiewicz Z. Effect of camptothecin on mitogenic stimulation of human lymphocytes: involvement of DNA topoisomerase I in cell transition form G0 to G1 phase of the cell cycle and DNA replication. J Cell Physiol 1992;151:47886.
  • 47
    Córtes F, Pastor N, Mateos S, Dominguez I. Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat Res 2003;543:5966.
  • 48
    Nakatsu S, Kondo S, Kondo Y et al. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 1997;39:41723.
  • 49
    Fenech M, Crott JW. Micronuclei, nucleoplasmic bridges and nuclear buds induced in folic acid deficient human lymphocytes – evidence for breakage-fusion cycles in the cytokinesis-block micronucleus assay. Mutat Res 2002;504:1316.
  • 50
    Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert E. Determinants of the cytotoxicity of irinotecan it two human colorectal tumor cell lines. Cancer Chemother Pharmacol 2002;49:329335.
  • 51
    Morton CL, Wadkins RM, Danks MK, Potter PM. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalized to SN-38 by butyrilcholinesterase. Cancer Res 1999;59:145863.
  • 52
    Shingyoji M, Takiguchi Y, Watanabe-Uruma R et al. In vitro conversion of irinotecan to SN-38 in human plasma. Cancer Sci 2004;95:53740.
  • 53
    Massoulié J, Anselmet A, Bon S et al. The polymorphism of acetylcholinesterase: post-translation processing, quaternary associations and localization. Chem Biol Interact 1999;119–120:2942.
  • 54
    Taylor P, Radic Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol 1994;34:281320.
  • 55
    Gandia D, Abigerges D, Armand JP et al. CPT-11-induced cholinergic effects in cancer patients (letter). J Clin Oncol 1993;11:1967.
  • 56
    Rowinsky EK, Grochow LB, Ettinger DS et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994;54:42736.
  • 57
    Pitot HC, Goldberg RM, Reid JM et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-3-week dosing schedule for patients with advanced solid tumour malignancy. Clin Cancer Res 2000;6:223644.
  • 58
    Taylor P. Anticholinesterase agents. In: HardmanJG, LimbirdLE, MalinoffPB, RuddonRW, GillmaAG (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. McGraw-Hill, New York, 1996;16176.
  • 59
    Yu QS, Atack JR, Rapoport SI, Brossi A. Carbamate analogues of (-)-physostigmine: in vitro inhibition of acetyl- and butyrylcholinesterase. FESB Lett 1988;234:12730.
  • 60
    Rampa A, Bisi A, Valenti P et al. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of ω-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]-aminoalkoxy-heteroaryl derivatives. J Med Chem 1998;41:397686.